Viridian Therapeutics, Inc.
VRDN
$28.68
$0.270.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -342.60M | -301.97M | -344.06M | -308.32M | -269.95M |
| Total Depreciation and Amortization | 460.00K | 163.00K | 483.00K | 512.00K | 540.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.72M | 33.70M | 29.08M | 27.36M | 27.49M |
| Change in Net Operating Assets | 23.03M | -57.86M | 5.44M | 701.00K | 9.60M |
| Cash from Operations | -276.39M | -325.97M | -309.06M | -279.75M | -232.32M |
| Capital Expenditure | -495.00K | -369.00K | -535.00K | -597.00K | -511.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -37.07M | 239.31M | 28.73M | 15.05M | -228.14M |
| Cash from Investing | -37.56M | 238.94M | 28.20M | 14.46M | -228.65M |
| Total Debt Issued | 28.88M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 366.99M | 58.08M | 282.19M | 281.64M | 459.68M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 25.00M | 25.00M | 25.00M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 30.88M | -1.73M | -16.67M | -16.77M | -26.94M |
| Cash from Financing | 426.74M | 56.36M | 290.52M | 289.87M | 457.74M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.79M | -30.67M | 9.66M | 24.57M | -3.23M |